Company news
Gensight Biologics SA news in 2026
Gensight Biologics SA's news releases, calls and decks from 2026, newest first.
GenSight Biologics Announces the Closing of its €1.0 Million Fundraising Supported by Existing Shareholders
October 16, 2026
GenSight Biologics Announces the Closing of its €1.0 Million Fundraising Supported by Existing Shareholders
October 15, 2026
Gensight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa
October 8, 2026
GenSight Biologics Announces a Successful €1.0 Million Fundraising Supported by Existing Shareholders
October 8, 2026
GenSight Biologics Reports Cash Position as of September 30, 2026
October 7, 2026
GenSight Biologics S A Reports Cash Position as of September 30, 2026
October 7, 2026
GenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business Updates
September 29, 2026
GenSight Biologics publie ses résultats financiers du premier semestre 2026 et fait un point sur son activité
September 29, 2026
GenSight Biologics S A Reports Interim Financial Results for the First Half of 2026 and Provides Business Updates
September 29, 2026
GenSight Biologics Provides September 2026 Business Updates
September 8, 2026
GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates
July 8, 2026
GenSight Biologics Announces the Results of its Combined General Meeting of May 19, 2026
May 20, 2026
GenSight Biologics to Hold its Combined General Meeting on May 19, 2026
May 18, 2026
GenSight Biologics Announces Publication on Matching-Adjusted Indirect Comparison of Leber Hereditary Optic Neuropathy Treatments
May 11, 2026
GenSight Biologics Announces Annual General Meeting to Take Place on May 19, 2026
April 28, 2026
GenSight Biologics Announces the Filing of its 2025 Universal Registration Document
April 15, 2026
GenSight Biologics Reports Cash Position and Revenue from Early Access Program as of March 31, 2026
April 7, 2026
GenSight Biologics Confirms Definitive Full-Year 2025 Consolidated Financial Results Are in Line with Estimates
April 3, 2026
GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025
March 27, 2026
The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ®
March 20, 2026
GenSight Biologics Announces the Closing of its Nearly €1.7 Million Fundraising
March 18, 2026
GenSight Biologics Announces Successful Fundraising Worth Nearly €1.7 Million
March 10, 2026
GenSight Biologics Provides Updates about GS010/LUMEVOQ® Early Access Programs and the Ongoing REVISE Study
March 9, 2026
GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments
February 18, 2026
The 15-20 National Hospital and GenSight Biologics Announce the Treatment of the First Patient in the GS010/LUMEVOQ® REVISE Study
February 10, 2026
GenSight Biologics Announces the Results of its Extraordinary General Meeting of January 28, 2026
January 28, 2026
GenSight Biologics Reports Cash Position as of December 31, 2025, and Provides Business Updates
January 8, 2026
GenSight Biologics Announces Closing of Fundraising Worth Nearly EUR 2.9 Million
January 7, 2026
Decks in 2026
- Shareholder Meeting (May 2026)
Shareholder meeting · 59 slides · May 19, 2026